Regulatory Actions and Inefficacy: Why Was Xenaderm Discontinued?
•
4 min read
In 2012, Xenaderm's manufacturer, Healthpoint Ltd., agreed to pay up to $48 million to resolve allegations of marketing an unapproved drug [1.2.2, 1.6.4]. The core of **why Xenaderm was discontinued** lies in regulatory non-compliance and questions about its effectiveness.
